CA2250723C - Multiple epitope fusion protein - Google Patents
Multiple epitope fusion protein Download PDFInfo
- Publication number
- CA2250723C CA2250723C CA2250723A CA2250723A CA2250723C CA 2250723 C CA2250723 C CA 2250723C CA 2250723 A CA2250723 A CA 2250723A CA 2250723 A CA2250723 A CA 2250723A CA 2250723 C CA2250723 C CA 2250723C
- Authority
- CA
- Canada
- Prior art keywords
- epitope
- epitopes
- hcv
- mefa
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020001507 fusion proteins Proteins 0.000 title description 6
- 102000037865 fusion proteins Human genes 0.000 title description 5
- 239000000427 antigen Substances 0.000 claims abstract description 97
- 102000036639 antigens Human genes 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 96
- 238000003556 assay Methods 0.000 claims abstract description 90
- 150000001413 amino acids Chemical class 0.000 claims abstract description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 51
- 238000003018 immunoassay Methods 0.000 claims abstract description 40
- 241000711549 Hepacivirus C Species 0.000 claims description 129
- 230000000890 antigenic effect Effects 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 37
- 241000700605 Viruses Species 0.000 claims description 34
- 108010076039 Polyproteins Proteins 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 230000004927 fusion Effects 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 208000005176 Hepatitis C Diseases 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 46
- 238000001514 detection method Methods 0.000 abstract description 21
- 244000052769 pathogen Species 0.000 abstract description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 14
- 230000001717 pathogenic effect Effects 0.000 abstract description 14
- 239000011248 coating agent Substances 0.000 abstract description 5
- 238000000576 coating method Methods 0.000 abstract description 5
- 239000000758 substrate Substances 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 4
- 230000000873 masking effect Effects 0.000 abstract description 3
- 230000001131 transforming effect Effects 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 39
- 239000000523 sample Substances 0.000 description 35
- 238000012360 testing method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000012895 dilution Substances 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 101710159910 Movement protein Proteins 0.000 description 13
- 101710144117 Non-structural protein 4 Proteins 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000013610 patient sample Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241001227713 Chiron Species 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FQQREHKSHAYSMG-UHFFFAOYSA-N 1,2-dimethylacridine Chemical compound C1=CC=CC2=CC3=C(C)C(C)=CC=C3N=C21 FQQREHKSHAYSMG-UHFFFAOYSA-N 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- -1 p24gag and p55gag Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- AAYSIOJYGRABGS-UHFFFAOYSA-N 3-[9-[4-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-2,6-dimethylphenoxy]carbonylacridin-10-ium-10-yl]propane-1-sulfonate Chemical compound C=1C(C)=C(OC(=O)C=2C3=CC=CC=C3[N+](CCCS([O-])(=O)=O)=C3C=CC=CC3=2)C(C)=CC=1C(=O)ON1C(=O)CCC1=O AAYSIOJYGRABGS-UHFFFAOYSA-N 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000007828 protein synthesis assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/653,226 US6514731B1 (en) | 1996-05-24 | 1996-05-24 | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens |
| US08/859,524 | 1997-05-20 | ||
| US08/653,226 | 1997-05-20 | ||
| US08/859,524 US6428792B1 (en) | 1996-05-24 | 1997-05-20 | Hepatitis C virus multiple copy epitope fusion antigens |
| PCT/US1997/008950 WO1997044469A2 (en) | 1996-05-24 | 1997-05-23 | Multiple epitope fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2250723A1 CA2250723A1 (en) | 1997-11-27 |
| CA2250723C true CA2250723C (en) | 2012-07-17 |
Family
ID=27096474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2250723A Expired - Lifetime CA2250723C (en) | 1996-05-24 | 1997-05-23 | Multiple epitope fusion protein |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0935662B1 (enExample) |
| JP (2) | JP3945822B2 (enExample) |
| AT (1) | ATE311463T1 (enExample) |
| AU (1) | AU719929B2 (enExample) |
| CA (1) | CA2250723C (enExample) |
| DE (1) | DE69734776T2 (enExample) |
| DK (1) | DK0935662T3 (enExample) |
| ES (1) | ES2251028T3 (enExample) |
| IL (1) | IL126460A (enExample) |
| NZ (1) | NZ333431A (enExample) |
| WO (1) | WO1997044469A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6322965B1 (en) * | 1997-02-10 | 2001-11-27 | Advanced Life Science Institute, Inc. | Chimera antigen peptide |
| US6261764B1 (en) | 1997-09-22 | 2001-07-17 | Chiron Corporation | Buffers for stabilizing antigens |
| CA2303123C (en) * | 1997-09-22 | 2006-04-11 | Chiron Corporation | Method for detecting antibodies in a sample |
| IL137458A0 (en) * | 1998-01-30 | 2001-07-24 | Gen Hospital Corp | Genetic immunization with nonstructural proteins of hepatitis c virus |
| ATE401340T1 (de) | 1998-04-17 | 2008-08-15 | Innogenetics Nv | Verfahren zur verbesserung der proteinkonformation mit hilfe von reduktionsmitteln |
| AU3714499A (en) * | 1998-05-14 | 1999-11-29 | Pasteur Merieux Serums Et Vaccins | Hepatitis c virus mimotopes |
| US7052696B2 (en) * | 1998-07-10 | 2006-05-30 | The United States Of America As Represented By The Department Of Health And Human Services | Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins |
| US6379903B1 (en) | 1999-10-08 | 2002-04-30 | Sigma-Aldrich Co. | Purification of recombinant proteins fused to multiple epitopes |
| JP2003512826A (ja) | 1999-10-27 | 2003-04-08 | カイロン コーポレイション | Ｈｃｖ特異的ｔ細胞の活性化 |
| ATE366582T1 (de) * | 1999-12-28 | 2007-08-15 | Pharmexa Inc | Optimierte minigene und dadurch kodierte peptide |
| US7491808B2 (en) | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
| EP1829891B1 (en) | 2000-06-15 | 2012-12-26 | Novartis Vaccines and Diagnostics, Inc. | Immunoassays for Anti-HCV Antibodies |
| ES2288969T3 (es) * | 2000-06-15 | 2008-02-01 | Novartis Vaccines And Diagnostics, Inc. | Inmunoensayos para anticuerpos anti-hcv. |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| MXPA05002641A (es) | 2002-09-09 | 2005-05-05 | Chiron Corp | Ensayo del virus de la hepatitis c. |
| EP1576125A4 (en) * | 2002-10-25 | 2008-09-03 | Novartis Vaccines & Diagnostic | ACTIVATION OF SPECIFIC HCV LYMPHOCYTES |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| ES2377978T3 (es) | 2004-08-27 | 2012-04-03 | Novartis Vaccines And Diagnostics, Inc. | Mutantes de proteínas no estructurales de VHC y usos de los mismos |
| JP5475279B2 (ja) * | 2005-06-17 | 2014-04-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｃ型肝炎ウイルス核酸ワクチン |
| EP1969001A2 (en) | 2005-11-22 | 2008-09-17 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and sapovirus antigens |
| AU2008335457B2 (en) | 2007-12-07 | 2015-04-16 | Glaxosmithkline Biologicals S.A. | Compositions for inducing immune responses |
| CN103282375B (zh) | 2010-12-02 | 2017-01-11 | 比奥诺尔免疫有限公司 | 肽支架设计 |
| CN103347892B (zh) | 2011-01-06 | 2016-11-02 | 比奥诺尔免疫有限公司 | 单体和多聚体免疫原性肽 |
| CA2863083C (en) * | 2012-01-26 | 2023-09-19 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| WO2013182661A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| AU2016215049B2 (en) | 2015-02-06 | 2021-12-02 | Cell Idx, Inc. | Antigen-coupled immunoreagents |
| ES2832335T3 (es) | 2015-03-27 | 2021-06-10 | Ortho Clinical Diagnostics Inc | Polipéptidos NS4A/NS3 modificado del VHC y usos de los mismos |
| CN109716130B (zh) * | 2016-07-18 | 2023-05-23 | 赛尔伊迪克斯公司 | 抗原偶联的杂交试剂 |
| KR101813586B1 (ko) * | 2016-12-29 | 2018-01-30 | 고려대학교 산학협력단 | 다양한 질병마커 인지 에피토프와 연결된 단백질 나노입자 및 이를 이용한 고민감도 질병마커 검출방법 |
| EP3658171B1 (en) * | 2017-07-27 | 2023-08-30 | Roche Diagnostics GmbH | Multi-epitope fusion protein of an hcv antigen and uses thereof |
| KR101871985B1 (ko) * | 2017-08-14 | 2018-06-27 | 고려대학교 산학협력단 | 3차원 단백질 나노입자 프로브 기반 복수 질환의 동시검출 방법 및 키트 |
| CN108794636B (zh) * | 2018-06-28 | 2020-05-22 | 中国人民解放军军事科学院军事医学研究院 | 一种表位多肽串联混合物在抗立氏立克次体的免疫保护中的应用 |
| KR102100813B1 (ko) * | 2018-11-08 | 2020-04-16 | 주식회사 보레다바이오텍 | C형 간염바이러스 유래 융합 단백질 및 이를 포함하는 진단키트 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69232871T2 (de) * | 1991-06-24 | 2003-05-08 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Polypeptide des hepatitis c-virus (hiv) |
| ES2300100T3 (es) * | 1991-10-16 | 2008-06-01 | Merck Patent Gmbh | Metodos para el diseño de peptidos de epitodo recombinado. |
| US5683695A (en) * | 1993-02-10 | 1997-11-04 | United Biomedical, Inc. | Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains |
| US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| GB2294047A (en) * | 1994-10-14 | 1996-04-17 | Merck & Co Inc | Synthetic peptides for use as epitopes specific for HIV |
-
1997
- 1997-05-23 DK DK97927767T patent/DK0935662T3/da active
- 1997-05-23 NZ NZ333431A patent/NZ333431A/xx not_active IP Right Cessation
- 1997-05-23 ES ES97927767T patent/ES2251028T3/es not_active Expired - Lifetime
- 1997-05-23 AU AU32143/97A patent/AU719929B2/en not_active Expired
- 1997-05-23 DE DE69734776T patent/DE69734776T2/de not_active Expired - Lifetime
- 1997-05-23 IL IL126460A patent/IL126460A/en not_active IP Right Cessation
- 1997-05-23 JP JP54284897A patent/JP3945822B2/ja not_active Expired - Lifetime
- 1997-05-23 CA CA2250723A patent/CA2250723C/en not_active Expired - Lifetime
- 1997-05-23 AT AT97927767T patent/ATE311463T1/de active
- 1997-05-23 WO PCT/US1997/008950 patent/WO1997044469A2/en not_active Ceased
- 1997-05-23 EP EP97927767A patent/EP0935662B1/en not_active Expired - Lifetime
-
2007
- 2007-02-06 JP JP2007027374A patent/JP2007127671A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL126460A0 (en) | 1999-08-17 |
| AU3214397A (en) | 1997-12-09 |
| AU719929B2 (en) | 2000-05-18 |
| ATE311463T1 (de) | 2005-12-15 |
| JP3945822B2 (ja) | 2007-07-18 |
| JP2007127671A (ja) | 2007-05-24 |
| WO1997044469A2 (en) | 1997-11-27 |
| DE69734776D1 (de) | 2006-02-09 |
| EP0935662B1 (en) | 2005-11-30 |
| CA2250723A1 (en) | 1997-11-27 |
| ES2251028T3 (es) | 2006-04-16 |
| NZ333431A (en) | 2000-05-26 |
| EP0935662A2 (en) | 1999-08-18 |
| DK0935662T3 (da) | 2006-03-06 |
| IL126460A (en) | 2007-07-04 |
| JP2001500723A (ja) | 2001-01-23 |
| DE69734776T2 (de) | 2006-08-17 |
| WO1997044469A8 (en) | 1999-07-22 |
| WO1997044469A3 (en) | 1997-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2250723C (en) | Multiple epitope fusion protein | |
| US6428792B1 (en) | Hepatitis C virus multiple copy epitope fusion antigens | |
| US6596476B1 (en) | Hepatitis C assay | |
| ES2134388T5 (es) | Combinaciones de antigenos del virus de la hepatitis c (hcv) para su uso en inmunoensayos para anticuerpos anti-hcv. | |
| US6312889B1 (en) | Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies | |
| US5683864A (en) | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies | |
| JP4427182B2 (ja) | 抗原を安定化するための緩衝液 | |
| JP3188717B2 (ja) | Ｃ型肝炎アッセイ | |
| US6727092B2 (en) | Methods for the simultaneous detection of HCV antigens and HCV antibodies | |
| EP0472207B1 (en) | Hepatitis C assay utilizing recombinant antigens | |
| EP0642666B1 (en) | Hepatitis c assay | |
| US20040185436A1 (en) | Methods for the simultaneous detection of HCV antigens and HCV antibodies | |
| JP5070055B2 (ja) | 改変タンパク分解性切断部位を有するｈｃｖ多エピトープ融合抗原およびその使用 | |
| Wienhues et al. | Characterization of a linear epitope in the nonstructural region 4 of hepatitis C virus with reactivity to seroconversion antibodies | |
| JP3327549B2 (ja) | Ｃ１００領域に対する組換え抗原を利用したｃ型肝炎アッセイ | |
| CA2082924A1 (en) | Assay for non-a non-b hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170523 |